631 related articles for article (PubMed ID: 29131884)
1. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.
Hamid SHM; Whittam D; Saviour M; Alorainy A; Mutch K; Linaker S; Solomon T; Bhojak M; Woodhall M; Waters P; Appleton R; Duddy M; Jacob A
JAMA Neurol; 2018 Jan; 75(1):65-71. PubMed ID: 29131884
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
6. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
8. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
[TBL] [Abstract][Full Text] [Related]
9. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
Pache F; Zimmermann H; Mikolajczak J; Schumacher S; Lacheta A; Oertel FC; Bellmann-Strobl J; Jarius S; Wildemann B; Reindl M; Waldman A; Soelberg K; Asgari N; Ringelstein M; Aktas O; Gross N; Buttmann M; Ach T; Ruprecht K; Paul F; Brandt AU;
J Neuroinflammation; 2016 Nov; 13(1):282. PubMed ID: 27802824
[TBL] [Abstract][Full Text] [Related]
10. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
11. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.
Mariano R; Messina S; Kumar K; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2019 Oct; 2(10):e1912732. PubMed ID: 31596489
[TBL] [Abstract][Full Text] [Related]
14. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
[TBL] [Abstract][Full Text] [Related]
16. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
17. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
[TBL] [Abstract][Full Text] [Related]
18. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
19. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis.
Martinez-Hernandez E; Sepulveda M; Rostásy K; Höftberger R; Graus F; Harvey RJ; Saiz A; Dalmau J
JAMA Neurol; 2015 Feb; 72(2):187-93. PubMed ID: 25506781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
